Apr 13, 2020

Regeneron Granted Fundamental Patents Covering Mouse Antibody Technology Used in VelocImmune® Mice

Posted by in categories: biotech/medical, genetics

Circa 2013

These patents form part of Regeneron’s global patent portfolio, which together protect fundamental inventions behind Regeneron’s VelocImmune humanized mice. The two patents listed above specifically contain claims covering genetically modified mice that have unrearranged human immunoglobulin variable region gene segments at endogenous mouse immunoglobulin loci. The VelocImmune mice contain the full repertoire of human heavy chain immunoglobulin genes and kappa light chain genes, each linked to endogenous mouse constant regions. As a result, VelocImmune mice generate a normal and robust immune response which many believe is becoming the gold standard for making human antibody therapeutics. VelocImmune is also proving to be one of the most valuable technologies in biotechnology history, in terms of the licensing and collaboration revenues it has helped generate.

TARRYTOWN, N.Y., Aug. 7, 2013 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the United States Patent and Trademark Office granted U.S. Patent No. 8,502,018 relating to methods of genetically modifying a mouse to make human antibodies. A similar European.

Comments are closed.